A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

MicroPort Orthopedics Optimizing its Episode of Care for Surgeons and Patients, Investing In New Technologies and Partnerships

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, is taking an Episode of Care approach to enhance operational efficiency and patient satisfaction throughout the 90 days both before and after surgery.

MicroPort is investing in new strategic technologies and partnerships with the vision to improve efficiencies, patient outcomes, and provider productivity.
Technologies built specifically around streamlining the Episode of Care ensure patients are prepared mentally and physically for their procedure and have digital resources to communicate with their doctors throughout the recovery process. Additionally, the resources can help healthcare providers monitor patients, predict risk, and manage outcomes.
To increase patient engagement and systematically measure patient outcomes, MicroPort recently partnered with PatientIQ, a platform that combines industry-leading patient engagement technology with research quality advanced analytics.
Together, PatientIQ and MicroPort Orthopedics are guiding the future of orthopedic care. With over 1,600 online education modules, PatientIQ provides a top-tier patient experience that can be specifically tailored to a procedure or a diagnosis. In addition to preoperatively educating and optimizing patients for their upcoming surgery, the platform also administers patient outcomes surveys and automates data collection throughout the entire Episode of Care to provide full service and support to both patients and surgeons.
MicroPort Orthopedics has also recently partnered with Dr. Aaron Salyapongse, orthopaedic surgeon in Dublin, California, to develop a Virtual Joint Class series moving patient education content to a digital format, allowing them to prepare for their upcoming surgery.
These classes, available through MicroPort’s proprietary PATHWAYS program, are specifically designed in a relatable and interactive blackboard style format to keep patients interested and engaged. They provide details about what to expect during and after the procedure. The classes not only introduce a breadth of topics including surgical preparation, anesthesia, discharge criteria, and post-op pain management, but also preemptively address many of the common causes for patient adverse events and readmissions.”
“Over the last 20 years, total joint replacement surgery has undergone a significant evolution. In the early 2000s, it was common for patients to spend days in a hospital for a procedure and then be moved to a skilled nursing facility for several weeks. Today, patients are routinely discharged hours after the procedure without any added risk and at a lower cost compared to a traditional inpatient setting,” said Benny Hagag, president of MicroPort Orthopedics.
Hagag concluded, “These systemic changes to the Episode of Care, combined with the impact of COVID-19 on today’s healthcare system, have required companies to adapt and prioritize innovation and technology at the center of care. Our recent collaboration and strategic partnerships with like-minded companies and surgeons are what keep us advancing toward positive patient outcomes and effective procedures, and we are only getting started.”
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy